Brokers Offer Predictions for WVE Q1 Earnings

Wave Life Sciences Ltd. (NASDAQ:WVE) – Research analysts at B. Riley issued their Q1 2025 earnings estimates for shares of Wave Life Sciences in a report released on Wednesday, November 13th. B. Riley analyst M. El-Saadi anticipates that the company will post earnings of ($0.25) per share for the quarter. B. Riley has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.09) per share. B. Riley also issued estimates for Wave Life Sciences’ Q2 2025 earnings at ($0.24) EPS.

A number of other research analysts have also recently commented on the company. Royal Bank of Canada lifted their price target on Wave Life Sciences from $7.00 to $15.00 and gave the company a “sector perform” rating in a research report on Monday, October 21st. JPMorgan Chase & Co. increased their price target on shares of Wave Life Sciences from $13.00 to $17.00 and gave the stock an “overweight” rating in a research note on Thursday, October 17th. Wells Fargo & Company boosted their price objective on shares of Wave Life Sciences from $11.00 to $22.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 16th. Leerink Partners raised their target price on shares of Wave Life Sciences from $20.00 to $22.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Finally, StockNews.com downgraded Wave Life Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $21.89.

Wave Life Sciences Price Performance

WVE stock opened at $13.67 on Friday. Wave Life Sciences has a 1 year low of $3.50 and a 1 year high of $16.74. The firm has a 50-day moving average of $10.76 and a 200 day moving average of $7.54. The company has a market cap of $2.08 billion, a P/E ratio of -12.32 and a beta of -1.20.

Insider Activity

In related news, CFO Kyle Moran sold 17,146 shares of Wave Life Sciences stock in a transaction on Wednesday, September 25th. The shares were sold at an average price of $9.00, for a total transaction of $154,314.00. Following the transaction, the chief financial officer now owns 19,777 shares in the company, valued at approximately $177,993. The trade was a 46.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Paul Bolno sold 51,234 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $14.32, for a total value of $733,670.88. Following the completion of the sale, the chief executive officer now owns 217,351 shares of the company’s stock, valued at $3,112,466.32. The trade was a 19.08 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 452,056 shares of company stock valued at $5,955,438 in the last ninety days. 29.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Emerald Advisers LLC purchased a new position in Wave Life Sciences during the 2nd quarter valued at approximately $12,441,000. Maverick Capital Ltd. increased its position in Wave Life Sciences by 31.0% in the third quarter. Maverick Capital Ltd. now owns 10,047,520 shares of the company’s stock worth $82,390,000 after purchasing an additional 2,378,159 shares during the last quarter. Emerald Mutual Fund Advisers Trust purchased a new stake in Wave Life Sciences during the second quarter valued at $9,086,000. Artal Group S.A. raised its stake in Wave Life Sciences by 34.7% during the first quarter. Artal Group S.A. now owns 4,051,400 shares of the company’s stock valued at $24,997,000 after purchasing an additional 1,044,000 shares in the last quarter. Finally, FMR LLC lifted its position in Wave Life Sciences by 174.5% during the third quarter. FMR LLC now owns 1,540,190 shares of the company’s stock valued at $12,630,000 after purchasing an additional 979,110 shares during the last quarter. 89.73% of the stock is owned by hedge funds and other institutional investors.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.